Louise C Young
Overview
Explore the profile of Louise C Young including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riley C, Ammar U, Alsfouk A, Anthony N, Baiget J, Berretta G, et al.
Molecules
. 2024 Aug;
29(15).
PMID: 39124921
The inhibitory-kappaB kinases (IKKs) IKKα and IKKβ play central roles in regulating the non-canonical and canonical NF-κB signalling pathways. Whilst the proteins that transduce the signals of each pathway have...
2.
Hughes A, Magot F, Tawfike A, Rad-Menendez C, Thomas N, Young L, et al.
Microorganisms
. 2021 Feb;
9(2).
PMID: 33546180
With more than 156,000 described species, eukaryotic algae (both macro- and micro-algae) are a rich source of biological diversity, however their chemical diversity remains largely unexplored. Specialised metabolites with promising...
3.
Anthony N, Baiget J, Berretta G, Boyd M, Breen D, Edwards J, et al.
J Med Chem
. 2017 Jul;
60(16):7043-7066.
PMID: 28737909
IKKβ plays a central role in the canonical NF-kB pathway, which has been extensively characterized. The role of IKKα in the noncanonical NF-kB pathway, and indeed in the canonical pathway...
4.
Obeid M, Elburi A, Young L, Mullen A, Tate R, Ferro V
Mol Pharm
. 2017 Jun;
14(7):2450-2458.
PMID: 28570823
Small interfering RNAs (siRNA) have a broad potential as therapeutic agents to reversibly silence any target gene of interest. The clinical application of siRNA requires the use of safe and...
5.
Alonezi S, Tusiimire J, Wallace J, Dufton M, Parkinson J, Young L, et al.
Metabolites
. 2017 Apr;
7(2).
PMID: 28420117
Melittin, the main peptide present in bee venom, has been proposed as having potential for anticancer therapy; the addition of melittin to cisplatin, a first line treatment for ovarian cancer,...
6.
Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode
Miller L, Keune W, Castagna D, Young L, Duffy E, Potjewyd F, et al.
J Med Chem
. 2016 Dec;
60(2):722-748.
PMID: 27982588
Autotaxin (ATX) is a secreted enzyme responsible for the hydrolysis of lysophosphatidylcholine (LPC) to the bioactive lysophosphatidic acid (LPA) and choline. The ATX-LPA signaling pathway is implicated in cell survival,...
7.
Alonezi S, Tusiimire J, Wallace J, Dufton M, Parkinson J, Young L, et al.
Metabolites
. 2016 Oct;
6(4).
PMID: 27754384
In the present study, liquid chromatography-mass spectrometry (LC-MS) was employed to characterise the metabolic profiles of two human ovarian cancer cell lines A2780 (cisplatin-sensitive) and A2780CR (cisplatin-resistant) in response to...
8.
Bansal R, Kumar G, Rohilla S, Klotz K, Kachler S, Young L, et al.
Drug Dev Res
. 2016 Jul;
77(5):241-50.
PMID: 27404511
Preclinical Research A new series of 1,3-dimethylxanthine derivatives bearing 8-(2-nitroaryl) residue was synthesized and evaluated for affinity for recombinant human adenosine receptors subtypes. Nitrate esters of 7-substituted-1,3-dimethyl-8-phenylxanthines were also synthesized...
9.
Purves K, MacIntyre L, Brennan D, Hreggvidsson G, Kuttner E, Asgeirsdottir M, et al.
Metabolites
. 2016 Jan;
6(1).
PMID: 26761036
The oceans represent an understudied resource for the isolation of bacteria with the potential to produce novel secondary metabolites. In particular, actinomyces are well known to produce chemically diverse metabolites...
10.
Harvey A, Young L, Kornisiuk E, Snitcofsky M, Colettis N, Blanco C, et al.
Behav Brain Res
. 2012 Jul;
234(2):184-91.
PMID: 22750535
Adenosine A(1) receptor antagonists are of potential value in the treatment of cognitive dysfunction. We have developed compound AJ23 (7-methyl-1-phenyl-1,8-dihydro-pyrazolo-(3,4d)(1,2,4)-triazolo(1,5a)-pyrimidin-4-one) as a novel, non-xanthine based antagonist at A(1) receptors. It...